Last updated on November 2018

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Brief description of study

The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.

Detailed Study Description

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The trial will also assess the effects of AMX0035 on muscle strength, vital capacity, and biomarkers of ALS including markers of neuronal death and neuroinflammation.

Clinical Study Identifier: NCT03127514

Contact Investigators or Research Sites near you

Start Over

Shafeeq Ladha, MD

Barrow Neurological Institute
Phoenix, AZ United States
  Connect »

Namita Goyal, MD

UC Irvine Medical Center
Orange, CA United States
  Connect »

Jonathan Katz, MD

Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
San Francisco, CA United States
  Connect »

James Wymer, MD

University of Florida Medical Center
Gainesville, FL United States
  Connect »

Tuan Vu, MD

Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
Tampa, FL United States
  Connect »

Christina Fournier, MD

Emory University Hospital
Atlanta, GA United States
  Connect »

Andrea Swenson, MD

University of Iowa Hospitals and Clinics
Iowa City, IA United States
  Connect »

Edward Kasarskis, M.D.

University of Kentucky Medical Center
Lexington, KY United States
  Connect »

Daniel Larriviere, MD

Ochsner Neuroscience Institute
New Orleans, LA United States
  Connect »

Jeffrey Rothstein, MD, PhD

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

James D Berry, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Margaret A Owegi, DO

University of Massachusetts Memorial Medical Center
Worcester, MA United States
  Connect »

Stephen Goutman, MD

University of Michigan Medical Center
Ann Arbor, MI United States
  Connect »

Cherie Martinson

Hennepin County Medical Center
Minneapolis, MN United States
  Connect »

Timothy Miller, MD

Washington University Medical Center
Saint Louis, MO United States
  Connect »

Gary Pattee, MD

Neurology Associates P.C.
Lincoln, NE United States
  Connect »

Stephen Scelsa, MD

Mount Sinai Beth Israel
New York, NY United States
  Connect »

James Caress, MD

Wake Forest Baptist Medical Center
Winston-Salem, NC United States
  Connect »

Adam Quick, MD

The Ohio State University Wexner Medical Center
Columbus, OH United States
  Connect »

Chafic Karam, MD

Oregon Health & Science University
Portland, OR United States
  Connect »

Colin Quinn, MD

The Penn Comprehensive ALS Center
Philadelphia, PA United States
  Connect »

Terry Heiman-Patterson, MD

Temple University Hospital
Philadelphia, PA United States
  Connect »

Daragh Heitzman, MD

Texas Neurology, P.A.
Dallas, TX United States
  Connect »

Carlayne Jackson, MD

University of Texas Health Science Center at San Antonio
San Antonio, TX United States
  Connect »

Michael Elliott, MD

ALS Center at the Swedish Neuroscience Institute
Seattle, WA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.